Novo Nordisk A/s

Dorte Xenia Gram

Peter Madsen

Palle Jakobsen

Patrick William Garibay

Thomas Hoeg-Jensen

Janos Tibor Kodra

Thomas Boerglum Kjeldsen

Thomas Børglum Kjeldsen

Tina Møller Tagmose

János Tibor Kodra

An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.

Insulin analogues with an acyl and alkylene glycol moiety

Acylated insulins wherein an acyl moiety is attached to the parent insulin and wherein the acyl moiety comprises repeating units of alkylene glycol containing amino acids and wherein there is only one lysine residue (K & Lys) in the parent insulin, having satisfactory properties when administered pulmonary.

Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids

Growing community of inventors

København Ø, Denmark

Dorte Xenia Gram